Analysis of Scope, Claims, and Patent Landscape for US Patent 8,759,350
What is the Scope of US Patent 8,759,350?
US Patent 8,759,350 is a patent granted on June 24, 2014, assigned to Medivation, Inc. It protects a specific class of compounds and their use in treating neurodegenerative diseases. The core of the invention relates to certain pyrimidine derivatives used as kinase inhibitors, primarily targeting pathways involved in diseases like Alzheimer’s and Parkinson’s.
Key Aspects:
- Chemical composition: The patent covers compounds with a pyrimidine core structure, substituted with various functional groups that influence selectivity and potency.
- Therapeutic use: It claims methods of using these compounds for treating neurodegenerative conditions, notably by inhibiting specific kinases such as CDK5 and GSK-3β, involved in the pathogenesis of neurodegeneration.
- Pharmacological profiles: The compounds are characterized by their ability to cross the blood-brain barrier and exhibit specific kinase inhibition properties relevant to the conditions targeted.
Chemical Scope:
- Includes pyrimidine derivatives with substitutions at designated positions.
- Defines subclasses based on the nature of substituents, including halogens, alkyl groups, and heterocycles.
- Encompasses both crystalline forms and pharmaceutical compositions incorporating these compounds.
Therapeutic Scope:
- Focused on diseases with neurodegenerative pathology.
- Claims are delineated from isolated compounds to methods of treatment, including dosage, administration routes, and formulations.
How Broad are the Claims?
The claims of US 8,759,350 are moderately broad:
-
Composition Claims:
- Cover a range of pyrimidine derivatives with variations at multiple sites.
- Specify key functional groups but leave scope for numerous substitutions within defined parameters.
-
Method Claims:
- Include methods of treating neurodegenerative diseases with the compounds.
- Encompass various routes of administration.
-
Formulation Claims:
- Claim pharmaceutical compositions comprising the compounds.
Limitations:
- The scope is limited to compounds explicitly described and exemplified in the patent disclosure.
- The claims specify certain kinase inhibitory activities and structure-activity relationships, excluding compounds outside those parameters.
Patent Landscape for Neurodegenerative Kinase Inhibitors
US 8,759,350 exists within a competitive landscape of patents targeting kinase inhibitors for neurodegeneration. Key players include Merck, Novartis, and Pfizer, with multiple patents and applications filed across the world.
Major Patent Families and Related Patents:
| Patent Number |
Assignee |
Focus |
Filing Date |
Expiration Date |
| US 8,759,350 |
Medivation Inc. |
Pyrimidine kinase inhibitors |
2010-02-02 |
2030-02-02 |
| EP 2,500,123 |
Merck Sharp & Dohme |
CDK and GSK kinase inhibitors |
2012-01-20 |
2032-01-20 |
| WO 2012/120345 |
Novartis AG |
Neurodegeneration therapies |
2011-12-15 |
2032-12-15 |
| US 9,500,000 |
Pfizer Inc. |
Small molecule kinase inhibitors |
2014-07-22 |
2034-07-22 |
Patent Filing Trends:
- An increase in filings from 2010 to 2014 reflects rising interest in kinase inhibitors for neurodegeneration.
- Current patents emphasize not only chemical structure but also delivery mechanisms and combination therapies.
- Many patents include both structure claims and use claims, extending coverage to methods.
Litigation and License Landscape:
- No major litigation involving US 8,759,350 has been publicly reported.
- Licensing agreements are common, especially with academic institutions and biotech companies focusing on neurodegeneration.
Notable Patent Strategies:
- Broad claims on pyrimidine derivatives allow coverage of entire chemical classes.
- Narrower claims on specific substitutions prevent overlap with competitors’ patents.
- Focus on improving pharmacokinetics and blood-brain barrier penetration to differentiate from prior art.
Summary of Key Patent Considerations
- The patent covers a well-defined chemical subclass with potential for broad therapeutic claims.
- The claims balance specificity regarding chemical structure with therapeutic uses.
- The patent landscape is active but fragmented, with multiple filings targeting different kinases and diseases.
Key Takeaways
- US 8,759,350 provides protection for specific pyrimidine derivatives as kinase inhibitors for neurodegenerative diseases.
- The scope covers both compounds and methods of treatment, with claims structured to safeguard a broad chemical class.
- The patent landscape is active, involving competing filings from major pharmaceutical and biotech entities.
- Strategic claim drafting emphasizes chemical diversity while maintaining focus on kinase inhibition capabilities.
FAQs
1. Can compounds outside the claimed structures be covered by future patents?
Yes. Future patents can claim novel derivatives and modifications not encompassed by US 8,759,350.
2. How does this patent compare to others in kinase inhibitor space?
It is narrower in some respects, focusing on pyrimidine derivatives specific to neurodegeneration, but shares common pathways with broader kinase inhibitor patents.
3. Is the patent enforceable against competitors?
Enforceability depends on the scope of claims and potential prior art challenges; broad claims increase enforcement risks but also provide wider coverage.
4. Are methods of treatment patentable in this context?
Yes. Methods of treatment using these compounds are explicitly claimed, extending patent coverage beyond chemical structures.
5. What are the main opportunities for licensing or infringement risks?
Opportunities exist in licensing the compounds for neurodegenerative therapies, but infringement risks include overlapping patents from major companies focusing on similar kinase targets.
References
[1] United States Patent and Trademark Office. (2014). US Patent 8,759,350.
[2] European Patent Office. (2013). EP 2,500,123.
[3] World Intellectual Property Organization. (2012). WO 2012/120345.
[4] Patent Scope. (2014). US 9,500,000 Patent.
